Novo Nordisk Completes Acquisition of Akero Therapeutics
Novo Nordisk has finalised its acquisition of Akero Therapeutics, making Akero a wholly owned subsidiary. Following the transaction, Akero’s common stock will cease trading on the Nasdaq Global Select Market.
Pharma Industry Acquisition Deal | 10/12/2025 | By Akanki
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy